Benzinga · Mar 6, 2026
TV
NASDAQ · TVGNW
Tevogen Bio Holdings Inc.
Healthcare · Biotechnology
$0.05
Up+$0.00 (+4.05%)
Updated Sep 14, 2026, 6:14 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.25M
- P/E ratio
- -2.7
- Dividend yield
- 0.00%
- 52-week range
- $0.03 – $0.06
- Volume
- 622.62K
- Avg. volume
- 111.92K
Price performance
TVGNW price history
1M range · 18 trading sessions · Daily adjusted prices
TVGNW closed at $0.05 after 18 trading sessions, down 0.96% for the selected period.
- Last close
- $0.05
- Period change
- -0.96%
- Period low
- $0.05
- Period high
- $0.05
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $0.0525 | $0.0535 | $0.0425 | $0.0518 | 622.62K |
| Sep 10, 2026 | $0.0469 | $0.0508 | $0.0451 | $0.0508 | 14.37K |
| Sep 9, 2026 | $0.0515 | $0.0523 | $0.0469 | $0.0514 | 192.52K |
| Sep 8, 2026 | $0.0521 | $0.0543 | $0.047 | $0.0528 | 215.55K |
| Sep 4, 2026 | $0.053 | $0.0545 | $0.0461 | $0.0521 | 225.17K |
| Sep 3, 2026 | $0.0515 | $0.0544 | $0.0471 | $0.0514 | 413.21K |
| Sep 2, 2026 | $0.0531 | $0.0535 | $0.0454 | $0.0525 | 620.15K |
| Sep 1, 2026 | $0.0525 | $0.0545 | $0.0452 | $0.0531 | 457.06K |
| Aug 31, 2026 | $0.0535 | $0.0545 | $0.045 | $0.05 | 209.42K |
| Aug 28, 2026 | $0.0522 | $0.0535 | $0.0522 | $0.0535 | 257.53K |
| Aug 27, 2026 | $0.0533 | $0.0544 | $0.0505 | $0.0522 | 381.13K |
| Aug 26, 2026 | $0.0494 | $0.0521 | $0.044 | $0.0521 | 208.86K |
| Aug 25, 2026 | $0.045 | $0.045 | $0.0448 | $0.045 | 771 |
| Aug 24, 2026 | $0.0515 | $0.053 | $0.0444 | $0.0452 | 83.08K |
| Aug 21, 2026 | $0.0515 | $0.0545 | $0.0442 | $0.05 | 114.61K |
| Aug 20, 2026 | $0.0495 | $0.0545 | $0.0495 | $0.05 | 145.55K |
| Aug 19, 2026 | $0.0426 | $0.0496 | $0.0426 | $0.0495 | 13.24K |
| Aug 17, 2026 | $0.0526 | $0.0526 | $0.0507 | $0.0523 | 251.4K |
Latest TVGNW news
The latest Smart Investors Daily articles mentioning TVGNW.
Stock researchCompany · Overview
TVGNW research
Overview
Company profile and research snapshot.
Company profile
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
GlobeNewswire Inc. · Dec 8, 2025
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
Tevogen Bio was recognized by NJBIZ for its innovative ExacTcell™ platform and AI technology, with projected near-term commercial potential of $1 billion in first-year revenue and a five-year forecast of $18-22 billion.
Yahoo · Nov 14, 2025
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when sustainability has become what the Company believes a defining challenge for the biotechnology industry. Tevogen reported a loss from operations calculated in accordance with U.S. GAAP of $5.7 million for the thre
GlobeNewswire Inc. · Nov 3, 2025
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
Tevogen Bio explains its accumulated deficit of $129 million, highlighting that the majority represents non-cash expenses and is offset by additional paid-in capital, with total cash loss under $42 million.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
